ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE and BONE LOSS

Overview

BONE LOSS is the #3 most commonly reported adverse reaction for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE, manufactured by Gilead Sciences, Inc.. There are 2,410 FDA adverse event reports linking ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE to BONE LOSS. This represents approximately 5.6% of all 43,023 adverse event reports for this drug.

Patients taking ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE who experience bone loss should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

BONE LOSS is moderately reported among ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE users, representing a notable but not dominant share of adverse events.

Other Side Effects of ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE

In addition to bone loss, the following adverse reactions have been reported for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE:

• BONE DENSITY DECREASED — 4,492 reports
• CHRONIC KIDNEY DISEASE — 2,605 reports
• OSTEONECROSIS — 2,378 reports
• TOOTH LOSS — 2,247 reports
• MULTIPLE FRACTURES — 2,131 reports
• RENAL FAILURE — 2,086 reports
• OSTEOPOROSIS — 1,928 reports
• RENAL INJURY — 1,916 reports
• PAIN — 1,857 reports
• EMOTIONAL DISTRESS — 1,803 reports

Other Drugs Associated with BONE LOSS

The following drugs have also been linked to bone loss in FDA adverse event reports:

Does ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE cause BONE LOSS?

BONE LOSS has been reported as an adverse event in 2,410 FDA reports for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is BONE LOSS with ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE?

BONE LOSS accounts for approximately 5.6% of all adverse event reports for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE, making it one of the most commonly reported side effect.

What should I do if I experience BONE LOSS while taking ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE?

If you experience bone loss while taking ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages